MRI is a diagnostic test that doctors use to diagnose and track the progress of amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that damages nerve cells in the brain and spinal cord.
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
A new drug for amyotrophic lateral sclerosis, or ALS, has cleared a major hurdle on its path toward being produced and ...
The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.
The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.
A team at IIT (BHU) is developing a revolutionary cell-based medical device using 3D bioprinting technology aimed at curing ...
Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...
Passage Bio (PASG) has received a new Buy rating, initiated by Wedbush analyst, Yun Zhong.Don't Miss our Black Friday Offers:Unlock your ...
Kentucky medical cannabis practitioners could begin writing certifications for medical cannabis treatment on Dec. 1. Local ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback